GI Onc Now Videos

Gabriel Brooks, MDGI Cancer | February 27, 2024
Dr. Brooks explains the association between male sex and 5-FU exposure.
View More
Thierry André, MDColorectal Cancer | February 12, 2024
Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting.
Kawther Abdilleh, PhDPancreatic Cancer | January 29, 2024
Dr. Abdilleh discusses PanCAN's new cloud-based data and analytics program for pancreatic cancer research.
Amit Mahipal, MDASCO GI 2024 | January 31, 2024
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Ethan Ludmir, MDASCO GI 2024 | January 25, 2024
Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma.
Elizabeth Conner, MDASCO GI 2024 | January 25, 2024
Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC.
Christopher Lieu, MDASCO GI 2024 | January 25, 2024
Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer.
Timothy Brown, MDASCO GI 2024 | January 29, 2024
Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab.
Yelena Janjigian, MDASCO GI 2024 | January 25, 2024
Dr. Yelena Janjigian discusses the results of the phase 3 MATTERHORN study at ASCO GI 2024.
Milind Javle, MDASCO GI 2024 | January 25, 2024
Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024.
Christopher Lieu, MDASCO GI 2024 | January 23, 2024
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024.
Julien Calderaro, MD, PhDHepatocellular Carcinoma | January 23, 2024
Dr. Julien Calderaro explains the potential of AI to serve as a biomarker of sensitivity to atezolizumab plus bevacizumab.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu conclude with considerations for managing IO-related toxicities in patients with metastatic HCC.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu continue their discussion with attention to biomarkers of response for immunotherapy in mHCC.
Namrata Vijayvergia, MDUnresectable HCC | January 23, 2024
Drs. Vijayvergia and Lieu detail the considerations for administering immunotherapy to their patients with metastatic HCC.
Josep M. Llovet, MDHepatocellular Carcinoma | January 23, 2024
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
Josep M. Llovet, MDHepatocellular Carcinoma | January 23, 2024
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
Michael Lidsky, MDColorectal Cancer | January 23, 2024
Drs. Lidsky and Eng discuss PUMP, a phase 3 trial of HAI for treating patients with CRC and unresectable liver metastases.
Amit Mahipal, MDHepatocellular Carcinoma | January 23, 2024
Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO.
Amit Mahipal, MDHepatocellular Carcinoma | January 23, 2024
Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.
Advertisement
Advertisement
Latest News

March 1, 2024